<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Novavax Inc. NVAX, -0.27% jumped 8.0% in premarket trading on Wednesday after the company said it began submitting its experimental COVID-19 vaccine for authorization in the U.K. Novavax’s vaccine candidate is protein-based, meaning it’s a different type of vaccine than the mRNA shots developed by BioNTech SE BNTX, -0.86% /Pfizer Inc. PFE, +0.95% and Moderna Inc. MRNA, -1.09% or the ChAdOx1 technology used in the AstraZeneca AZN, +0.79% shots. Novavax’s vaccine came out of clinical trials in the U.K. with an overall efficacy rate of 89.7%.
...read full article on Market Watch
